The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer

The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer

Bibliographic Details
Main Authors:	Atsushi Tanaka, MD, PhD, Koichi Node, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	JACC. CardioOncology
Subjects:	androgen deprivation therapy cardiometabolic syndrome cardiovascular disease prostate cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666087319300730

Similar Items

The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
by: Omer Faruk Kirlangic, PhD, et al.
Published: (2020-06-01)

Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections
by: Sooraj Kakkat, et al.
Published: (2023-04-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Dong‐Yi Chen, et al.
Published: (2023-10-01)

Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
by: Andrew W. Hahn, et al.
Published: (2023-09-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
by: R Miralbell, et al.
Published: (2009-09-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study
by: Justinas Jonušas, et al.
Published: (2022-12-01)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
by: James Fradin, et al.
Published: (2023-04-01)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
by: Szu-Yuan Wu, et al.
Published: (2020-01-01)

Impact of tumor cytoreduction in metastatic prostate cancer
by: Sow Y, et al.
Published: (2019-05-01)

Remission of Membranous Nephropathy after Treatment of Localised Prostate Cancer
by: Daniel Adlington, et al.
Published: (2019-06-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
by: Maryam Labaf, et al.
Published: (2022-11-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

The effect of estradiol add-back: a longitudinal MRI study in prostate cancer patients
by: Orwa Dandash, et al.
Published: (2024-02-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Endocrine manipulations in cancer prostate: A review
by: Rajesh Rajput, et al.
Published: (2012-01-01)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
by: Norman J. Maitland
Published: (2021-01-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)

Association of Androgen Deprivation Therapy with Osteoporotic Fracture in Patients with Prostate Cancer with Low Tumor Burden Using a Retrospective Population-Based Propensity-Score-Matched Cohort
by: Sung Han Kim, et al.
Published: (2023-05-01)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
by: Maree Pechlivanis, et al.
Published: (2021-12-01)

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study
by: Vaios-Konstantinos Mytilekas, et al.
Published: (2023-11-01)

Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
by: A. Gomez-Iturriaga, et al.
Published: (2024-03-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
by: Niraj Kumar, et al.
Published: (2022-06-01)

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
by: Choi E, et al.
Published: (2022-03-01)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
by: Yong Jin Kang, et al.
Published: (2017-11-01)

Dramatic mixed response of lymphangitic pulmonary metastases in newly diagnosed prostate cancer
by: Elan Gorshein, et al.
Published: (2017-01-01)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
by: Kenichi Hata, et al.
Published: (2022-11-01)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
by: Nicolaas Lumen, et al.
Published: (2021-07-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis
by: Bakhya Shree, et al.
Published: (2023-07-01)

Dysfunctional Lipid Metabolism—The Basis for How Genetic Abnormalities Express the Phenotype of Aggressive Prostate Cancer
by: Matthew Alberto, et al.
Published: (2023-01-01)